B. Riley Boosts Earnings Estimates for Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Stock analysts at B. Riley boosted their Q3 2025 earnings per share (EPS) estimates for shares of Eton Pharmaceuticals in a research report issued on Wednesday, July 16th. B. Riley analyst M. El-Saadi now forecasts that the company will post earnings of $0.16 per share for the quarter, up from their previous forecast of $0.15. B. Riley currently has a “Buy” rating and a $26.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ Q4 2025 earnings at $0.42 EPS, FY2026 earnings at $1.06 EPS and FY2027 earnings at $1.74 EPS.

ETON has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $35.00 target price (up from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday, May 29th. Craig Hallum lifted their price objective on Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, May 14th.

Eton Pharmaceuticals Price Performance

Eton Pharmaceuticals stock opened at $15.02 on Friday. Eton Pharmaceuticals has a 52-week low of $3.25 and a 52-week high of $21.48. The firm has a market capitalization of $402.84 million, a price-to-earnings ratio of -83.44 and a beta of 1.18. The company has a quick ratio of 1.43, a current ratio of 1.97 and a debt-to-equity ratio of 1.23. The company has a fifty day simple moving average of $16.14 and a 200-day simple moving average of $15.31.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). Eton Pharmaceuticals had a negative net margin of 9.49% and a negative return on equity of 3.15%. The business had revenue of $17.28 million during the quarter, compared to analysts’ expectations of $14.33 million.

Institutional Trading of Eton Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. AlphaQuest LLC purchased a new position in Eton Pharmaceuticals in the first quarter worth approximately $53,000. Tower Research Capital LLC TRC acquired a new position in shares of Eton Pharmaceuticals in the 4th quarter valued at $86,000. Quantbot Technologies LP acquired a new position in shares of Eton Pharmaceuticals in the 1st quarter valued at $101,000. Jefferies Financial Group Inc. purchased a new position in shares of Eton Pharmaceuticals during the 4th quarter worth $133,000. Finally, Point72 Asia Singapore Pte. Ltd. grew its holdings in shares of Eton Pharmaceuticals by 18.3% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company’s stock worth $141,000 after purchasing an additional 1,634 shares during the period. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Insider Transactions at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, insider David Krempa sold 10,223 shares of Eton Pharmaceuticals stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $14.73, for a total transaction of $150,584.79. Following the transaction, the insider directly owned 612,646 shares of the company’s stock, valued at $9,024,275.58. The trade was a 1.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 34,000 shares of company stock worth $504,318 in the last ninety days. 16.03% of the stock is currently owned by company insiders.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.